The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Role of tumor infiltrating lymphocytes (TILs) in HER2+ metastatic breast cancers (MBC) treated with trastuzumab emtansine (T-DM1) or lapatinib plus capecitabine (L+C) (EMILIA Trial).
 
Sunil S. Badve
Speakers' Bureau - Genentech
 
Yesim Gokmen-Polar
No Relationships to Disclose
 
Silke Hoersch
Employment - Roche/Genentech
 
Jin Xu
Employment - Genentech
Stock and Other Ownership Interests - Roche
 
Josef Ruschoff
Employment - Targovax
Leadership - Targovax
Stock and Other Ownership Interests - Targovax
Research Funding - Roche/Genentech
 
Sanne de Haas
Employment - Roche/Genentech
 
Sunil Verma
Honoraria - Amgen; AstraZeneca; Boehringer Ingelheim; Merck; Novartis; Pfizer; Roche/Genentech
Consulting or Advisory Role - Amgen; AstraZeneca; Eisai; Lilly; Novartis; Roche/Genentech